{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:18:58Z","timestamp":1784899138980,"version":"3.55.0"},"reference-count":106,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.3892\/ijo.2016.3460","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T06:34:28Z","timestamp":1459146868000},"page":"2221-2235","source":"Crossref","is-referenced-by-count":43,"title":["Hormone signaling pathways as treatment targets in renal cell cancer (Review)"],"prefix":"10.3892","volume":"48","author":[{"given":"ANNA M.","family":"CZARNECKA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAGDALENA","family":"NIEDZWIEDZKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAMILLO","family":"PORTA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CEZARY","family":"SZCZYLIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"key":"key20180107185705_b1-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1586\/14737140.2014.941815","article-title":"The use of sunitinib in renal cell carcinoma: Where are we now?","volume":"14","author":"Czarnecka","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180107185705_b2-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"key20180107185705_b3-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1188\/09.CJON.S2.3-7","article-title":"Renal cell carcinoma: Screening, diagnosis, and prognosis","volume":"13","author":"Wood","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"key20180107185705_b4-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key20180107185705_b5-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key20180107185705_b6-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejca.2013.08.021","article-title":"Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials","volume":"50","author":"Molina","year":"2014","journal-title":"Eur J Cancer"},{"key":"key20180107185705_b7-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br J Cancer"},{"key":"key20180107185705_b8-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.4161\/cc.22794","article-title":"Estrogen receptor \u03b1 is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions","volume":"11","author":"Jung","year":"2012","journal-title":"Cell Cycle"},{"key":"key20180107185705_b9-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/carcin\/bgn275","article-title":"von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR","volume":"30","author":"Danilin","year":"2009","journal-title":"Carcinogenesis"},{"key":"key20180107185705_b10-ijo-48-06-2221","first-page":"31","article-title":"Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms","volume":"1845","author":"Buczek","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"key20180107185705_b11-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1574362409666140206222746","article-title":"Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma","volume":"8","author":"Kornakiewicz","year":"2014","journal-title":"Curr Signal Transduct Ther"},{"key":"key20180107185705_b12-ijo-48-06-2221","first-page":"4340","article-title":"Human renal cell carcinoma as a hormone-dependent tumor","volume":"38","author":"Concolino","year":"1978","journal-title":"Cancer Res"},{"key":"key20180107185705_b13-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jso.2930220305","article-title":"Measurement of progesterone receptor in human renal cell carcinoma and normal renal tissue","volume":"22","author":"McDonald","year":"1983","journal-title":"J Surg Oncol"},{"key":"key20180107185705_b14-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000473074","article-title":"Renal cancer steroid receptors: Biochemical basis for endocrine therapy","volume":"5","author":"Concolino","year":"1979","journal-title":"Eur Urol"},{"key":"key20180107185705_b15-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000473142","article-title":"Renal cancer steroid receptors: Biochemical basis for endocrine therapy","volume":"5","author":"Concolino","year":"1979","journal-title":"Eur Urol"},{"key":"key20180107185705_b16-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jcb.25278","article-title":"RU486 induces pro-apoptotic endoplasmic reticulum stress through the induction of CHOP expression by enhancing C\/EBPdelta expression in human renal carcinoma Caki cells","volume":"117","author":"Jang","year":"2015","journal-title":"J Cell Biochem"},{"key":"key20180107185705_b17-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/ijc.23750","article-title":"Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer","volume":"123","author":"Zucchetto","year":"2008","journal-title":"Int J Cancer"},{"key":"key20180107185705_b18-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjc.6603629","article-title":"A cohort study of reproductive and hormonal factors and renal cell cancer risk in women","volume":"96","author":"Kabat","year":"2007","journal-title":"Br J Cancer"},{"key":"key20180107185705_b19-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1038\/srep09160","article-title":"Age-dependent association between sex and renal cell carcinoma mortality: A population-based analysis","volume":"5","author":"Qu","year":"2015","journal-title":"Sci Rep"},{"key":"key20180107185705_b20-ijo-48-06-2221","first-page":"188","article-title":"Peptide hormones LH, FSH, TSH, prolactin, beta-HCG and PTH in patients with urogenital tumors","volume":"4","author":"Dunzendorfer","year":"1981","journal-title":"Onkologie"},{"key":"key20180107185705_b21-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3892\/or_00000525","article-title":"Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (Review)","volume":"22","author":"Aguilar-Rojas","year":"2009","journal-title":"Oncol Rep"},{"issue":"Suppl Int","key":"key20180107185705_b22-ijo-48-06-2221","first-page":"5","article-title":"Physiology of somatostatin receptors","volume":"28","author":"Guillermet-Guibert","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"key20180107185705_b23-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.5.5.613","article-title":"The biology and physiology of somatostatin receptors","volume":"5","author":"Lu","year":"2001","journal-title":"Expert Opin Ther Targets"},{"key":"key20180107185705_b24-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/carcin\/bgm106","article-title":"Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: Evidence for a critical role for integrin-linked kinase and nuclear factor kappa B","volume":"28","author":"Agouni","year":"2007","journal-title":"Carcinogenesis"},{"key":"key20180107185705_b25-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J Urol"},{"key":"key20180107185705_b26-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.urolonc.2010.07.015","article-title":"The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study","volume":"30","author":"Baldazzi","year":"2012","journal-title":"Urol Oncol"},{"key":"key20180107185705_b27-ijo-48-06-2221","first-page":"1873","article-title":"Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway","volume":"27","author":"Liao","year":"2012","journal-title":"Oncol Rep"},{"key":"key20180107185705_b28-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: Blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"key20180107185705_b29-ijo-48-06-2221","first-page":"13","article-title":"Clinical significance of peptide hormones LH, FSH, TSH, prolactin, HCG, parathormone, calcitonin and prostaglandin F2 alpha in kidney neoplasms","volume":"74","author":"Dunzendorfer","year":"1981","journal-title":"Z Urol Nephrol"},{"key":"key20180107185705_b30-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/j.1582-4934.2011.01495.x","article-title":"Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib","volume":"16","author":"Siraj","year":"2012","journal-title":"J Cell Mol Med"},{"key":"key20180107185705_b31-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1043-2760(99)00209-X","article-title":"Antagonistic analogs of growth Hormone-releasing hormone: New potential antitumor agents","volume":"10","author":"Schally","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"key20180107185705_b32-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ncpendmet0677","article-title":"Antagonists of growth-hormone-releasing hormone: An emerging new therapy for cancer","volume":"4","author":"Schally","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"key20180107185705_b33-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1073\/pnas.94.11.5810","article-title":"Growth hormone-releasing hormone antagonist MZ-4\u201371 inhibits in vivo proliferation of Caki-I renal adenocarcinoma","volume":"94","author":"Jungwirth","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107185705_b34-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1073\/pnas.180313097","article-title":"Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone","volume":"97","author":"Halmos","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107185705_b35-ijo-48-06-2221","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.6_suppl.469","article-title":"Effect of novel growth hormone-releasing hormone antagonists on growth of experimental renal cell carcinomas","volume":"31","author":"Rick","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107185705_b36-ijo-48-06-2221","first-page":"2974","article-title":"Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma","volume":"80","author":"Viki\u0107-Topi\u0107","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180107185705_b37-ijo-48-06-2221","first-page":"F1095","article-title":"Human proximal tubular epithelial cells express somatostatin: Regulation by growth factors and cAMP","volume":"274","author":"Turman","year":"1998","journal-title":"Am J Physiol"},{"key":"key20180107185705_b38-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3413\/nukmed-0119","article-title":"Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC","volume":"47","author":"Freudenberg","year":"2008","journal-title":"Nuklearmedizin"},{"key":"key20180107185705_b39-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00345-009-0417-x","article-title":"Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: Disruption of an endogenous inhibitor of angiogenesis and proliferation","volume":"27","author":"Tezval","year":"2009","journal-title":"World J Urol"},{"key":"key20180107185705_b40-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2407-13-199","article-title":"Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer","volume":"13","author":"Tezval","year":"2013","journal-title":"BMC Cancer"},{"key":"key20180107185705_b41-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1023\/A:1018947430018","article-title":"Passive transepithelial absorption of thyrotropin-releasing hormone (TRH) via a para-cellular route in cultured intestinal and renal epithelial cell lines","volume":"10","author":"Thwaites","year":"1993","journal-title":"Pharm Res"},{"key":"key20180107185705_b42-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/carcin\/bgs177","article-title":"Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas","volume":"33","author":"Arai","year":"2012","journal-title":"Carcinogenesis"},{"key":"key20180107185705_b43-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-04-2464","article-title":"Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues","volume":"11","author":"Keller","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107185705_b44-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1517\/13543784.2012.685128","article-title":"AEZS-108: A targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors","volume":"21","author":"Engel","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180107185705_b45-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<909::AID-CNCR16>3.0.CO;2-4","article-title":"Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II","volume":"82","author":"Jungwirth","year":"1998","journal-title":"Cancer"},{"key":"key20180107185705_b46-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/0008-5472.CAN-03-0145","article-title":"Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma","volume":"64","author":"Choi","year":"2004","journal-title":"Cancer Res"},{"key":"key20180107185705_b47-ijo-48-06-2221","article-title":"The growth hormone receptor","author":"Waters","year":"2015","journal-title":"Growth Horm IGF Res"},{"key":"key20180107185705_b48-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1210\/me.2014-1174","article-title":"Human GH receptor-IGF-1 receptor interaction: Implications for GH signaling","volume":"28","author":"Gan","year":"2014","journal-title":"Mol Endocrinol"},{"key":"key20180107185705_b49-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2169\/internalmedicine.48.1916","article-title":"Acromegaly associated with multiple tumors","volume":"48","author":"Sekizawa","year":"2009","journal-title":"Intern Med"},{"key":"key20180107185705_b50-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/BF02934094","article-title":"A rare case of gastric cancer in an acromegalic patient","volume":"32","author":"Asai","year":"1997","journal-title":"J Gastroenterol"},{"key":"key20180107185705_b51-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"e0122958","DOI":"10.1371\/journal.pone.0122958","article-title":"Association of thyroid diseases with primary extra-thyroidal malignancies in women: Results of a cross-sectional study of 6,386 patients","volume":"10","author":"Prinzi","year":"2015","journal-title":"PLoS One"},{"key":"key20180107185705_b52-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.clgc.2014.11.002","article-title":"Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"13","author":"Bailey","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"key20180107185705_b53-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clgc.2014.10.002","article-title":"Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic rmenal cell carcinoma treated with tyrosine kinase inhibitors: A literature-based meta-analysis","volume":"13","author":"Nearchou","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"key20180107185705_b54-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1471-2407-13-246","article-title":"Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases","volume":"13","author":"Siraj","year":"2013","journal-title":"BMC Cancer"},{"key":"key20180107185705_b55-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1001283","article-title":"Expression of follicle-stimulating hormone receptor in tumor blood vessels","volume":"363","author":"Radu","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107185705_b56-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.urolonc.2012.03.005","article-title":"The follicle-stimulating hormone receptor: A novel target in genitourinary malignancies","volume":"31","author":"Gartrell","year":"2013","journal-title":"Urol Oncol"},{"key":"key20180107185705_b57-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/en.2008-0850","article-title":"Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone","volume":"150","author":"Alam","year":"2009","journal-title":"Endocrinology"},{"key":"key20180107185705_b58-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)44738-0","article-title":"Prolactin secreting renal cell carcinoma","volume":"136","author":"Stanisic","year":"1986","journal-title":"J Urol"},{"key":"key20180107185705_b59-ijo-48-06-2221","doi-asserted-by":"crossref","DOI":"10.5772\/26993","article-title":"Steroid receptors in renal cell carcinoma","volume-title":"Emerging Research and Treatments in Renal Cell Carcinoma","author":"Yakirevich","year":"2012"},{"key":"key20180107185705_b60-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mce.2004.07.013","article-title":"Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids","volume":"226","author":"Iwai","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"key20180107185705_b61-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.humpath.2011.01.014","article-title":"Expression of the glucocorticoid receptor in renal cell neoplasms: An immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study","volume":"42","author":"Yakirevich","year":"2011","journal-title":"Hum Pathol"},{"key":"key20180107185705_b62-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00109-011-0821-8","article-title":"Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2","volume":"90","author":"Min","year":"2012","journal-title":"J Mol Med Berl"},{"key":"key20180107185705_b63-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000280277","article-title":"The endocrine background of human renal cell carcinoma. III Role of inhibitors of R 5020 binding in tumour cytosol","volume":"34","author":"Bojar","year":"1979","journal-title":"Urol Int"},{"key":"key20180107185705_b64-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000280278","article-title":"The endocrine background of human renal cell carcinoma. IV Glucocorticoid receptors as possible mediators of progestogen action","volume":"34","author":"Bojar","year":"1979","journal-title":"Urol Int"},{"key":"key20180107185705_b65-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/07357900701638418","article-title":"The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro","volume":"26","author":"Arai","year":"2008","journal-title":"Cancer Invest"},{"key":"key20180107185705_b66-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/02841860500400995","article-title":"Unexpected 10 years complete remission after cortisone mono-therapy in metastatic renal cell carcinoma","volume":"45","author":"Christophersen","year":"2006","journal-title":"Acta Oncol"},{"key":"key20180107185705_b67-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31815f2362","article-title":"Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: A tissue microarray and quantitative RT-PCR study","volume":"32","author":"Yakirevich","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"key20180107185705_b68-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/iep.12074","article-title":"Evidence for aldosterone-dependent growth of renal cell carcinoma","volume":"95","author":"King","year":"2014","journal-title":"Int J Exp Pathol"},{"key":"key20180107185705_b69-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"key20180107185705_b70-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI4445","article-title":"Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2","volume":"103","author":"Kotelevtsev","year":"1999","journal-title":"J Clin Invest"},{"key":"key20180107185705_b71-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3892\/ijo.2013.2204","article-title":"Vitamin D receptor gene polymorphisms in breast and renal cancer: Current state and future approaches (Review)","volume":"44","author":"Khan","year":"2014","journal-title":"Int J Oncol"},{"key":"key20180107185705_b72-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(17)44487-9","article-title":"1,25-Dihydroxyvitamin D3 receptors and their relationship to histological features in renal cell carcinoma","volume":"137","author":"Nagakura","year":"1987","journal-title":"J Urol"},{"key":"key20180107185705_b73-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.humpath.2006.04.029","article-title":"Expression of vitamin D3 receptor in kidney tumors","volume":"37","author":"Liu","year":"2006","journal-title":"Hum Pathol"},{"key":"key20180107185705_b74-ijo-48-06-2221","first-page":"2458","article-title":"1,25-Dihydro\u2212xyvitamin D3 receptor measurement in primary renal cell carcinomas and autologous normal kidney tissue","volume":"48","author":"Trydal","year":"1988","journal-title":"Cancer Res"},{"key":"key20180107185705_b75-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1159\/000070239","article-title":"Vitamin D receptor binding to DNA is altered without the change in its expression in human renal clear cell cancer","volume":"93","author":"Madej","year":"2003","journal-title":"Nephron Exp Nephrol"},{"key":"key20180107185705_b76-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jsbmb.2010.03.069","article-title":"Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer","volume":"121","author":"Blomberg Jensen","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20180107185705_b77-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/01.ju.0000108040.14303.c2","article-title":"Steroid hormone receptor expression in renal cell carcinoma: An immunohistochemical analysis of 182 tumors","volume":"171","author":"Langner","year":"2004","journal-title":"J Urol"},{"key":"key20180107185705_b78-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0022-5347(01)63098-2","article-title":"Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma","volume":"160","author":"Fujioka","year":"1998","journal-title":"J Urol"},{"key":"key20180107185705_b79-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1158\/1940-6207.CAPR-10-0122","article-title":"A vitamin D receptor-alkylating derivative of 1\u03b1,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth","volume":"3","author":"Lambert","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"key20180107185705_b80-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.juro.2007.05.119","article-title":"Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma","volume":"178","author":"Obara","year":"2007","journal-title":"J Urol"},{"key":"key20180107185705_b81-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180107185705_b82-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","article-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"22","author":"Atzpodien","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180107185705_b83-ijo-48-06-2221","first-page":"2647","article-title":"Nuclear retention of all steroid hormone receptor classes in the hamster renal carcinoma","volume":"39","author":"Li","year":"1979","journal-title":"Cancer Res"},{"key":"key20180107185705_b84-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"329","DOI":"10.11613\/BM.2014.035","article-title":"The many faces of estrogen signaling","volume":"24","author":"Vrta\u010dnik","year":"2014","journal-title":"Biochem Med Zagreb"},{"key":"key20180107185705_b85-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.2910260610","article-title":"Comparison of steroid receptor levels in renal-cell carcinoma and autologous normal kidney","volume":"26","author":"Hemstreet","year":"1980","journal-title":"Int J Cancer"},{"key":"key20180107185705_b86-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/modpathol.3800958","article-title":"Estrogen and progesterone-receptor-positive stroma as a non-tumorous proliferation in kidneys: A possible metaplastic response to obstruction","volume":"21","author":"Tickoo","year":"2008","journal-title":"Mod Pathol"},{"issue":"Suppl 1","key":"key20180107185705_b87-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1476-069X-11-S1-S8","article-title":"Environmental exposure to xenoestrogens and oestrogen related cancers: Reproductive system, breast, lung, kidney, pancreas, and brain","volume":"11","author":"Fucic","year":"2012","journal-title":"Environ Health"},{"key":"key20180107185705_b88-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/00000478-200007000-00007","article-title":"Mixed epithelial and stromal tumor of the kidney","volume":"24","author":"Adsay","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"key20180107185705_b89-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/carcin\/18.7.1375","article-title":"Induction of cathepsin D protein during estrogen carcinogenesis: Possible role in estrogen-mediated kidney tubular cell damage","volume":"18","author":"Li","year":"1997","journal-title":"Carcinogenesis"},{"key":"key20180107185705_b90-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ssu.2980040304","article-title":"Hormone receptors in renal cancer: An overview","volume":"4","author":"Jakse","year":"1988","journal-title":"Semin Surg Oncol"},{"key":"key20180107185705_b91-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0303-7207(03)00071-6","article-title":"Estrogen receptor alpha polymorphisms and renal cell carcinoma - a possible risk","volume":"202","author":"Tanaka","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"key20180107185705_b92-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0006-291X(02)02045-4","article-title":"Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma","volume":"296","author":"Tanaka","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107185705_b93-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"e56667","DOI":"10.1371\/journal.pone.0056667","article-title":"Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-\u03b2 activation","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"key":"key20180107185705_b94-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"19290","DOI":"10.18632\/oncotarget.4478","article-title":"Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa\/HIF2\u03b1 and estrogen receptor \u03b2 signals","volume":"6","author":"Song","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107185705_b95-ijo-48-06-2221","first-page":"6","article-title":"Expression of Ki-67, p53, bcl-2, estrogen receptors alpha in patients with clear cell renal carcinoma and epidermal growth factor receptor mutation","volume":"73","author":"Ivantsov","year":"2011","journal-title":"Arkh Patol"},{"key":"key20180107185705_b96-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1055\/s-0028-1093802","article-title":"Effect of the antiestrogen nafoxidine on the occurrence of estrogen-dependent renal tumors in hamster","volume":"6","author":"Antonio","year":"1974","journal-title":"Horm Metab Res"},{"key":"key20180107185705_b97-ijo-48-06-2221","first-page":"1581","article-title":"Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma","volume":"15","author":"Wada","year":"1995","journal-title":"Anticancer Res"},{"key":"key20180107185705_b98-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/41.5.8468448","article-title":"Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues","volume":"41","author":"Kimura","year":"1993","journal-title":"J Histochem Cytochem"},{"key":"key20180107185705_b99-ijo-48-06-2221","first-page":"55","article-title":"Hormone receptor immunoreactivity in heman-gioblastomas and clear cell renal cell carcinomas","volume":"11","author":"Brown","year":"1998","journal-title":"Mod Pathol"},{"key":"key20180107185705_b100-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.urology.2014.03.056","article-title":"Re: Zhu et al: The expression and evaluation of androgen receptor in human renal cell carcinoma (Urology 2014;83:510.e19\u201324)","volume":"84","author":"Putz","year":"2014","journal-title":"Urology"},{"key":"key20180107185705_b101-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"510.e519","DOI":"10.1016\/j.urology.2013.10.022","article-title":"The expression and evaluation of androgen receptor in human renal cell carcinoma","volume":"83","author":"Zhu","year":"2014","journal-title":"Urology"},{"key":"key20180107185705_b102-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1158\/0008-5472.CAN-13-2681","article-title":"ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2\u03b1\/VEGF signaling pathway","volume":"74","author":"He","year":"2014","journal-title":"Cancer Res"},{"key":"key20180107185705_b103-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/1097-0142(19850701)56:1<134::AID-CNCR2820560121>3.0.CO;2-J","article-title":"Increased dihydrotestosterone receptor levels in high-stage renal adenocarcinoma","volume":"56","author":"Noronha","year":"1985","journal-title":"Cancer"},{"key":"key20180107185705_b104-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0022-5347(17)49577-2","article-title":"Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy","volume":"132","author":"Nakano","year":"1984","journal-title":"J Urol"},{"key":"key20180107185705_b105-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/1097-0142(19840801)54:3<477::AID-CNCR2820540316>3.0.CO;2-K","article-title":"Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide","volume":"54","author":"Ahmed","year":"1984","journal-title":"Cancer"},{"key":"key20180107185705_b106-ijo-48-06-2221","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3892\/mmr.2014.2766","article-title":"Expression analysis of the estrogen receptor target genes in renal cell carcinoma","volume":"11","author":"Liu","year":"2015","journal-title":"Mol Med Rep"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2016.3460\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T21:11:58Z","timestamp":1567717918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2016.3460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":106,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,3,28]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.3892\/ijo.2016.3460"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2016.3460","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,28]]}}}